Akcea Therapeutics Announces Positive Phase 2 Study Results
- Posted by ISPE Boston
- On February 5, 2020
On January 28th, Boston-based Akcea Therapeutics and Ionis Pharmaceuticals, headquartered in Carlsbad, CA, announced positive Phase 2 study results of an oligonucleotide treatment of hypertriglyceridemia, type 2 diabetes and non-alcoholic fatty liver disease (NAFLD). The oligonucleotide, AKCEA-ANGPTL3-LRx, functions by an antisense-mediated reduction of angiopoietin-like 3 (ANGPTL3) protein in the liver. The antisense oligonucleotide is a […]
Read More